Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements

British Journal of Cancer

Volumn 108, Issue 9, 2013, Pages 1810-1816

  You, B ^a   Harvey, R ^b   Henin, E ^a   Mitchell, H ^b   Golfier, F ^a   Savage, P M ^b   Tod, M ^a   Wilbaux, M ^a   Freyer, G ^a   Seckl, M J ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Chorionic gonadotropin; Decision support techniques; Drug resistance; Gestational trophoblastic neoplasia; Methotrexate; Neoplasm; Prognosis

Indexed keywords

CHORIONIC GONADOTROPIN; FOLINIC ACID; METHOTREXATE;

ADULT; ARTICLE; CHORIOCARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE RESISTANCE; FAILURE FREE SURVIVAL; FEMALE; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; POPULATION DYNAMICS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REPRODUCIBILITY; TREATMENT DURATION; TROPHOBLASTIC TUMOR;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHORIONIC GONADOTROPIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; METHOTREXATE; MULTIVARIATE ANALYSIS; PREGNANCY; ROC CURVE; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84878529600     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.123     Document Type: Article

References (30)

1. Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35: 401-421.
2. Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ (2013) EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31: 280-286.
3. Bagshawe KD (1992) Choriocarcinoma. A model for tumour markers. Acta Oncol 31: 99-106.
4. Bagshawe KD, Dent J, Newlands ES, Begent RH, Rustin GJ (1989) The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 96: 795-802.
5. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28: 481-504.
6. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM User's Guides (1989-2009). Icon: Ellicott City, MD, USA.
7. Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. Aaps J 11: 371-380.
8. Bidart JM, Thuillier F, Augereau C, Chalas J, Daver A, Jacob N, Labrousse F, Voitot H (1999) Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 45: 1695-1707.
9. Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23: 2036-2049.
10. Chalouhi GE, Golfier F, Soignon P, Massardier J, Guastalla JP, Trillet-Lenoir V, Schott AM, Raudrant D (2009) Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. Am J Obstet Gynecol 200: 643-646.
11. Dartois C, Brendel K, Comets E, Laffont CM, Laveille C, Tranchand B, Mentre F, Lemenuel-Diot A, Girard P (2007) Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey 1. Br J Clin Pharmacol 64: 603-612.
12. Foulmann K, Guastalla JP, Caminet N, Trillet-Lenoir V, Raudrant D, Golfier F, Schott AM (2006) What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 102: 103-110.
13. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS (2009a) Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 112: 353-357.
14. Growdon WB, Wolfberg AJ, Goldstein DP, Feltmate CM, Chinchilla ME, Lieberman ES, Berkowitz RS (2009b) Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol 112: 353-357.
15. Harvey RA, Mitchell HD, Stenman UH, Blankenstein MA, Nustad K, Stieber P, Stewart W, Savage PM, Seckl MJ, Braunstein GD (2010) Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med 55: 285-295.
16. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64.
17. Kerkmeijer LG, Thomas CM, Harvey R, Sweep FC, Mitchell H, Massuger LF, Seckl MJ (2009) External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. Br J Cancer 100: 979-984.
18. Kohorn EI (2001) The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 11: 73-77.
19. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75: 85-94.
20. Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM (2011) Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 29: 825-831.
21. Patel SM, Desai A (2010) Management of drug resistant gestational trophoblastic neoplasia. J Reprod Med 55: 296-300.
22. Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P, Seckl MJ (2007) A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 96: 732-737.
23. Savage P, Seckl M, Short D (2008) Practical issues in the management of lowrisk gestational trophoblast tumors. J Reprod Med 53: 774-780.
24. Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376: 717-729.
25. Sita-Lumsden A, Short D, Lindsay I, Sebire NJ, Adjogatse D, Seckl MJ, Savage PM (2012) Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 107: 1810-1814.
26. Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
27. The R Development CT (2010) R: A Language and Environment for Statistical Computing. R2120 edR Foundation for Statistical Computing: Vienna, Austria.
28. van Trommel NE, Massuger LF, Schijf CP, ten Kate-Booij MJ, Sweep FC, Thomas CM (2006) Early identification of resistance to first-line singleagent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 24: 52-58.
29. You B, Deng W, Oza A, Osborne B (2012) Validation of the predictive value of modeled hCG residual production "P" in low-risk gestational trophoblastic neoplasia (GTN) patients treated in GOG-174 phase III trial. Proceedings of the 2012 ASCO Annual Meeting. Abs 5110.
30. You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F (2010) Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 21: 1643-1650.